By Catherine Eckford (European Pharmaceutical Review)2024-10-31T19:09:22
The Itovebi-based combination therapy was recently granted US FDA approval for a common metastatic breast cancer.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-03-27T15:37:00
Sponsored by IMA Pharma
2026-04-30T10:37:00
Sponsored by Shimadzu
2025-09-24T15:24:00
Sponsored by Lonza
2026-03-04T15:00:00 2026-03-04T16:00:00
Sponsored by METTLER TOLEDO
2025-11-20T15:00:00
Sponsored by Rapid Micro Biosystems
Site powered by Webvision Cloud